|
Title
|
|
|
|
Role of progranulin as a biomarker for Alzheimer's disease
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Serum or plasma progranulin (GRN) is a highly accurate predictor of GRN-related frontotemporal lobar degeneration, which is caused by loss-of-function mutations in the GRN gene. Both null mutations and missense mutations in GRN have also been observed in patients with Alzheimer's disease. Here, the evidence for a role of circulating GRN as a biochemical biomarker in neurodegeneration is reviewed, with a specific focus on its relevance in Alzheimer's disease. We conclude that circulating GRN is a promising, nonintrusive biomarker that warrants screening in both patients with dementia of the Alzheimer type and people with mild cognitive impairment; specifically for, but not limited to, those that have a positive family history of neurodegenerative disease. Once a cure for GRN-related neurodegeneration becomes available, this biomarker will be an important tool in the effort to personalize treatment of dementia. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Biomarkers in medicine
| |
|
Publication
|
|
|
|
2010
| |
|
ISSN
|
|
|
|
1752-0363
1752-0371
| |
|
DOI
|
|
|
|
10.2217/BMM.09.82
| |
|
Volume/pages
|
|
|
|
4
:1
(2010)
, p. 37-50
| |
|
ISI
|
|
|
|
000274512800005
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|